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Abstract
Lanosterol is a precursor for cholesterol, which is synthesized primarily in the liver in a pathway often described
as the mevalonate or HMG-CoA reductase pathway. The first two steps (formation of acetoacetyl CoA and the
mitochondrial generation of (S)-3-hydroxy-3-methylglutaryl-CoA) are also associated with oxidation of fatty
acids.
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